Wegovy: What to Expect Week by Week in Your First Month

Why the First Month Is a Dose-Titration Phase, Not a Weight-Loss Phase

The first four weeks on Wegovy are entirely at the 0.25 mg starting dose. That dose is sub-therapeutic for weight loss. Its purpose is tolerability. The body's GLP-1 receptors in the gut, brain, and pancreas need gradual exposure to avoid overwhelming nausea, vomiting, or gastroparesis symptoms.

Patients who understand this upfront are far less likely to stop the medication prematurely when the scale barely moves in week two. The 14.9% mean body-weight loss reported in STEP-1 took 68 weeks to accumulate. Month one is the foundation that makes those long-term results possible. [1]

The Full 17-Week Titration Schedule

| Week Range | Weekly Dose | |---|---| | Weeks 1 to 4 | 0.25 mg | | Weeks 5 to 8 | 0.5 mg | | Weeks 9 to 12 | 1.0 mg | | Weeks 13 to 16 | 1.7 mg | | Week 17+ | 2.4 mg (maintenance) |

Each step lasts four weeks. If a patient cannot tolerate a given dose after four weeks, the prescribing clinician may extend that dose level by an additional four weeks before advancing.

What "Once Weekly" Actually Means Pharmacokinetically

Semaglutide has a half-life of approximately seven days, which is why once-weekly dosing produces stable plasma concentrations. Novo Nordisk's FDA-approved prescribing information confirms that peak concentration (Tmax) occurs 24 to 72 hours after subcutaneous injection, meaning your highest drug exposure in week one lands roughly mid-week after a Monday injection. [2] Knowing this helps patients anticipate when nausea is most likely to hit.

Week 1: First Injection and Early Signals

Most patients feel something within 48 to 72 hours of their first 0.25 mg injection. The signals are subtle: a slightly earlier sense of fullness at meals, reduced interest in snacking between meals, and occasionally a faint low-grade nausea that fades within a few hours.

What the Body Is Actually Doing

Semaglutide binds GLP-1 receptors in the hypothalamic arcuate nucleus, reducing appetite-driving signals, and simultaneously slows gastric emptying. Both effects begin at dose one. The gastric-emptying slowdown is the direct cause of that early fullness and mild queasiness.

A 2021 mechanistic review in Diabetes Care confirmed that GLP-1 receptor agonists reduce gastric emptying rate by 20 to 30% at therapeutic doses, contributing directly to the nausea most patients experience early on. [3]

Practical Week-1 Actions

Eat smaller meals. The 0.25 mg dose reduces hunger modestly, and if patients continue eating previous portion sizes, nausea is more intense. Avoid high-fat meals immediately after injection days. Staying well-hydrated matters. Picking a consistent injection day, for example every Sunday morning, makes it easier to track patterns and schedule any anticipated fatigue.

Injection sites include abdomen (at least two inches from the navel), upper thigh, and upper arm. Rotating sites weekly reduces the small risk of lipohypertrophy.

Week 2: Nausea Typically Peaks Here

Week two is the most commonly reported difficult stretch of the entire titration, not just month one. Drug levels are now accumulating toward their first steady-state approximation, and the gastric-slowing effect is more pronounced.

Understanding the Nausea Pattern

Nausea from semaglutide is dose-dependent and time-limited. In STEP-1, 44% of participants in the semaglutide group reported nausea compared with 16% in the placebo group, but fewer than 5% discontinued due to nausea alone. [1] The nausea typically peaks 24 to 48 hours post-injection and then recedes. By the third or fourth week at any given dose, most patients report that nausea has diminished substantially.

The FDA prescribing information for Wegovy classifies nausea as the most common adverse reaction, occurring in 44% of patients, followed by diarrhea (30%), vomiting (24%), and constipation (24%). [2]

Managing Week-2 Nausea Without Stopping the Medication

Four strategies have clear clinical rationale:

• Eat bland, low-fat foods on injection day and the day after. Foods high in fat delay gastric emptying further, stacking with the drug's own effect.
• Avoid lying flat immediately after eating. Remaining upright for 30 to 45 minutes after meals reduces reflux triggered by slowed gastric transit.
• Consider ginger. A Cochrane review of ginger for nausea found modest but consistent benefit across multiple etiologies. [4] It is not a substitute for dose adjustment but may help with mild symptoms.
• Discuss anti-emetics with your prescriber if nausea prevents adequate hydration. Ondansetron 4 mg as needed is sometimes prescribed short-term during titration.

Week 3: Appetite Suppression Becomes Noticeable

By week three, most patients report a clearer, more consistent reduction in hunger. Food cravings, particularly for high-calorie foods, often diminish. Some patients describe feeling full after eating half their usual portion. This is the GLP-1 central effect becoming more apparent as the drug's action at hypothalamic and reward-circuit receptors builds.

The "Food Noise" Reduction Many Patients Notice

"Food noise" is the colloquial term for intrusive thoughts about food. Patients often describe it as thinking about what they will eat next even while still eating a current meal. GLP-1 receptor agonists appear to reduce this through dopaminergic pathways in the nucleus accumbens, not just through gut-mediated satiety signals.

A 2022 study published in Nature Metabolism demonstrated that semaglutide reduces the activation of reward-related brain regions in response to high-calorie food cues, providing a neurobiological explanation for the reduced food preoccupation patients report. [5]

Weight Changes at Week 3

Patients are often disappointed that the scale has only moved one to two pounds by week three. This is expected and normal. At 0.25 mg, the caloric reduction is modest. Any weight change at this stage is almost entirely from reduced caloric intake, water weight from glycogen depletion, and reduced bowel content secondary to constipation.

Constipation affects roughly one in four patients. Increasing dietary fiber to 25 to 35 grams per day, staying hydrated with 64 to 80 oz of water daily, and gentle movement all help. If constipation persists beyond week two at a given dose, osmotic laxatives such as polyethylene glycol 17 g daily are generally well tolerated and do not interfere with semaglutide absorption.

Week 4: Completing the Starter Dose and Preparing for Dose Escalation

Week four is the final week at 0.25 mg. Patients who have moved through weeks one through three without severe adverse effects are on track to advance to 0.5 mg beginning week five.

Assessing Your Tolerability Before Advancing

Before the week-five injection, patients should honestly assess three things:

1. Is nausea controllable, meaning it does not prevent eating or drinking adequately?
2. Has any injection-site reaction (redness, nodule, or itching lasting more than 48 hours) occurred?
3. Has any abdominal pain been severe or persistent? Severe, persistent abdominal pain radiating to the back warrants immediate evaluation to rule out pancreatitis, a rare but listed risk of GLP-1 receptor agonists.

The American Association of Clinical Endocrinology (AACE) 2023 Obesity Clinical Practice Guidelines state: "GLP-1 receptor agonists should be initiated at low doses and titrated slowly to minimize gastrointestinal adverse effects while maintaining therapeutic adherence." [6]

What Has Actually Changed After Four Weeks

By the end of week four, the average patient on Wegovy has lost one to three pounds, primarily through modest caloric reduction. More important than scale weight is what is happening metabolically. Fasting insulin levels may already be trending downward, and postprandial glucose spikes are blunted from the drug's glucose-dependent insulinotropic effect.

A practical four-week readiness checklist for dose advancement:

| Assessment | Green Light | Caution: Consider Extending 0.25 mg | |---|---|---| | Nausea severity | Mild, resolves within 48h | Moderate to severe, persistent | | Oral intake | Normal to slightly reduced | Significantly reduced | | Hydration | Adequate | Difficulty keeping fluids down | | Abdominal pain | None or mild and brief | Severe, persistent, or radiating | | Injection-site reactions | None or minimal | Nodules, significant erythema |

Early Side Effects: A Clinical Summary for Month One

Side effects in the first month are almost exclusively gastrointestinal and injection-related. Understanding them by mechanism helps patients manage rather than panic.

Gastrointestinal Side Effects

Nausea and vomiting result directly from slowed gastric emptying and central GLP-1 receptor activation. Nausea peaks in the first 48 hours post-injection at each new dose and diminishes over the subsequent two to four weeks at that dose. Vomiting is less common; if it occurs more than twice per week or prevents hydration, contact your prescriber.

Constipation is related to reduced colonic motility from GLP-1 receptor activation in the enteric nervous system. It affects approximately 24% of semaglutide users in trial data [1] and typically responds to increased fiber and fluid intake.

Diarrhea affects about 30% of patients, often alternating with constipation in the first weeks. It usually resolves without intervention by week three or four.

Burping and bloating are less commonly discussed but reported by patients. These stem from delayed gastric emptying causing gas accumulation. Avoiding carbonated beverages and eating slowly with thorough chewing reduces severity.

Fatigue and Energy Changes

Some patients report mild fatigue in week one and two, most often in the 24 to 48 hours post-injection. The mechanism is not fully defined. Reduced caloric intake combined with the drug's central nervous system effects likely contribute. Fatigue rarely persists beyond week three at any single dose level.

Injection-Site Reactions

Mild injection-site reactions such as transient redness or minor bruising occur in roughly 3 to 5% of patients. Using the auto-injector pen as directed, allowing the pen to reach room temperature before injection (30 minutes out of the refrigerator), and rotating injection sites weekly minimizes these reactions.

Lifestyle Factors That Determine How Much Weight You Lose in Month One and Beyond

Wegovy is approved as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone treatment. The label language from the FDA-approved prescribing information specifies this explicitly. [2]

Nutrition in Month One

The drug suppresses appetite, but patients still need to make deliberate food choices. Because stomach emptying is slower, protein and fiber become even more important: protein maintains lean muscle mass during weight loss, and fiber supports bowel regularity.

A minimum protein target of 1.2 grams per kilogram of body weight per day is reasonable during active weight loss on GLP-1 therapy. A 90 kg (200 lb) patient should aim for 108 grams of protein daily. Spreading this across three to four small meals works better than trying to consume it in one or two sittings given the early satiety from the drug.

Exercise and Muscle Preservation

In STEP-1, participants were asked to maintain a 500 kcal/day deficit diet plus 150 minutes of physical activity per week. The 14.9% weight loss result reflects that combined intervention. Patients who exercise, particularly with resistance training two to three times per week, preserve lean body mass better during the caloric restriction the drug induces.

A 2021 secondary analysis from the STEP program, published in Obesity, found that fat mass accounted for the majority of weight lost with semaglutide, but lean mass losses were still observed (approximately 39% of total weight lost was lean tissue in the absence of structured resistance training). [7] Resistance training can shift that ratio favorably.

Realistic Expectations: What Month One Weight Loss Actually Looks Like

The competitive field of internet content about Wegovy often over-promises early results. Patients sometimes read anecdotal reports of eight to ten pound losses in the first month and feel they are failing when they lose two pounds.

What the Trial Data Shows for Early Weeks

STEP-1 reported overall 68-week outcomes. Sub-group analyses and the dose-titration design make it clear that the first 16 weeks (during which patients are still dose-escalating) account for only a fraction of total weight loss. The drug does not reach its full 2.4 mg maintenance dose until week 17 at the earliest.

A phase 2 dose-finding trial for semaglutide published in The Lancet found that at lower doses (0.05 mg to 0.3 mg weekly), mean weight loss at 12 weeks was 2.1 to 4.2 kg. [8] The 0.25 mg starting dose of Wegovy sits at the low end of that range, confirming that one to three pounds in week four is consistent with the pharmacological reality.

The Psychological Dimension

Clinicians who prescribe GLP-1 receptor agonists frequently note that setting accurate expectations in week one prevents early discontinuation. The Obesity Medicine Association published a 2021 position statement noting that "patient education regarding the expected timeline of weight loss with pharmacotherapy is a key component of therapeutic success." [9]

Patients who stick through the titration phase and reach maintenance dose see meaningfully different results. In STEP-1, patients achieving at least 5% weight loss by week 28 had an 84% probability of achieving at least 10% weight loss by week 68. Early patience predicts long-term success.

When to Call Your Prescriber

Certain symptoms warrant prompt clinical contact, not a wait-and-see approach.

Call or message your prescriber if:

• Vomiting prevents you from keeping down liquids for more than 12 hours
• Abdominal pain is severe, constant, or radiates to the back (rule out pancreatitis)
• You develop vision changes, palpitations, or signs of hypoglycemia if also taking sulfonylureas or insulin
• A lump or swelling appears in the neck (rare theoretical thyroid C-cell risk; Wegovy carries a black-box warning for this in rodents, though human relevance is not established)
• Severe injection-site reactions develop beyond mild redness

The FDA prescribing label lists medullary thyroid carcinoma family history and multiple endocrine neoplasia syndrome type 2 as absolute contraindications. [2] These should be screened before starting Wegovy, not discovered during treatment.

Month One by the Numbers: A Quick Reference

| Timepoint | Expected Weight Loss | Primary Experience | |---|---|---| | Day 3 to 5 | 0 to 0.5 lb | First drug-level peak; possible mild nausea | | Week 1 end | 0 to 1 lb | Subtle appetite reduction; injection technique learning | | Week 2 end | 0.5 to 1.5 lb | Nausea often peaks; food portions beginning to shrink naturally | | Week 3 end | 1 to 2.5 lb | Food noise reduction; constipation may need management | | Week 4 end | 1 to 3 lb | Completing starter dose; preparing for 0.5 mg step-up |